[go: up one dir, main page]

AR075028A1 - Composicion farmaceutica solida que comprende amlodipina y losartan - Google Patents

Composicion farmaceutica solida que comprende amlodipina y losartan

Info

Publication number
AR075028A1
AR075028A1 ARP100100112A ARP100100112A AR075028A1 AR 075028 A1 AR075028 A1 AR 075028A1 AR P100100112 A ARP100100112 A AR P100100112A AR P100100112 A ARP100100112 A AR P100100112A AR 075028 A1 AR075028 A1 AR 075028A1
Authority
AR
Argentina
Prior art keywords
losartan
pharmaceutical composition
solid pharmaceutical
amlodipina
composition including
Prior art date
Application number
ARP100100112A
Other languages
English (en)
Inventor
Ji Hyun Im
Jong Soo Woo
Jae Hyun Park
Kyeong Soo Kim
Ho Taek Yim
Yong Ii Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42306870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR075028A1 publication Critical patent/AR075028A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se relaciona con una composicion farmacéutica solida para prevenir o tratar trastornos cardiovasculares que comprende amlodipina y losartán como ingredientes activos, y un desintegrador que es una mezcla de al menos dos componentes seleccionados del grupo que consiste de glicolato de almidon de sodio, croscarmelosa sodica y crospovidona, que exhibe un nivel alto y estable de velocidades de disolucion de amlodipina y losartán. Reivindicacion 4: La composicion de acuerdo con la reivindicacion 1, caracterizada porque el desintegrador se usa en una cantidad que oscila entre alrededor del 2,5 y alrededor del 30% en peso sobre la base del peso total de la composicion.
ARP100100112A 2009-01-23 2010-01-19 Composicion farmaceutica solida que comprende amlodipina y losartan AR075028A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090005840 2009-01-23
KR1020090090540A KR101160151B1 (ko) 2009-01-23 2009-09-24 암로디핀 및 로자탄을 함유하는 고형 약제학적 조성물

Publications (1)

Publication Number Publication Date
AR075028A1 true AR075028A1 (es) 2011-03-02

Family

ID=42306870

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP090100916A AR070897A1 (es) 2009-01-23 2009-03-13 Composicion farmaceutica solida que comprende amilodipina y losartan y proceso para producir la misma
ARP100100111A AR075027A1 (es) 2009-01-23 2010-01-19 Composicion farmaceutica solida que comprende amlodipina y losartan con estabilidad mejorada
ARP100100112A AR075028A1 (es) 2009-01-23 2010-01-19 Composicion farmaceutica solida que comprende amlodipina y losartan

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP090100916A AR070897A1 (es) 2009-01-23 2009-03-13 Composicion farmaceutica solida que comprende amilodipina y losartan y proceso para producir la misma
ARP100100111A AR075027A1 (es) 2009-01-23 2010-01-19 Composicion farmaceutica solida que comprende amlodipina y losartan con estabilidad mejorada

Country Status (32)

Country Link
US (3) US9161933B2 (es)
EP (3) EP2413931B1 (es)
JP (3) JP5658172B2 (es)
KR (2) KR101232296B1 (es)
CN (4) CN102292085B (es)
AR (3) AR070897A1 (es)
AU (3) AU2009338267B2 (es)
BR (3) BRPI0924136B8 (es)
CA (3) CA2749903C (es)
CL (1) CL2011001781A1 (es)
CO (3) CO6361914A2 (es)
CR (3) CR20110448A (es)
DO (3) DOP2011000229A (es)
EA (3) EA020103B1 (es)
EC (1) ECSP11011253A (es)
ES (3) ES2580777T3 (es)
HN (2) HN2011002022A (es)
IL (3) IL214146A0 (es)
JO (2) JO2981B1 (es)
MA (3) MA33056B1 (es)
MX (3) MX349221B (es)
MY (3) MY173823A (es)
NI (3) NI201100143A (es)
NZ (3) NZ594738A (es)
PE (4) PE20100559A1 (es)
SA (1) SA110310070B1 (es)
SG (3) SG173044A1 (es)
TW (3) TWI404534B (es)
UA (3) UA102721C2 (es)
UY (2) UY32389A (es)
WO (3) WO2010085014A1 (es)
ZA (3) ZA201106161B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0924136B8 (pt) 2009-01-23 2021-05-25 Hanmi Holdings Co Ltd composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
JP6160263B2 (ja) * 2012-06-07 2017-07-12 大正製薬株式会社 ロキソプロフェン含有医薬組成物
KR101506148B1 (ko) * 2013-09-24 2015-03-26 대봉엘에스 주식회사 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
WO2015072700A1 (en) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Composite formulation comprising tadalafil and amlodipine
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
KR101914930B1 (ko) 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
CN108156807A (zh) * 2015-06-30 2018-06-12 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
CN116637115A (zh) * 2017-05-27 2023-08-25 广州喜鹊医药有限公司 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用
CN107260735A (zh) * 2017-07-25 2017-10-20 合肥华方医药科技有限公司 生物利用度提高的二氢吡啶类药物组合物
CN107308159A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高伊拉地平生物利用度药物组合物
CN107308158A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高非洛地平生物利用度的药物组合物
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108542891A (zh) * 2018-06-07 2018-09-18 董贵雨 一种含有替格瑞洛的固体药物组合物
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법
KR102900997B1 (ko) 2019-12-11 2025-12-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
CN115666564B (zh) 2020-06-09 2024-07-16 韩美药品株式会社 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法
WO2025224756A1 (en) * 2024-04-23 2025-10-30 Mestastop Solutions Private Limited Composition, method and use thereof for delaying primary tumor metastasis using amlodipine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2179067A1 (en) 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
EP1872797A3 (en) 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
AU2002363087A1 (en) 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
WO2003048135A1 (en) 2001-11-14 2003-06-12 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
MXPA05007876A (es) 2003-01-27 2005-09-21 Hanmi Pharm Ind Co Ltd Camsilato de amlodipino amorfo, estable, proceso para preparar el mismo y composicion para la administracion oral del mismo.
WO2005007046A2 (en) * 2003-07-18 2005-01-27 Pneu Medex Inc. Fluid operated actuators and pneumatic unloading orthoses
EP1653950B1 (en) 2003-07-31 2008-01-09 NicOx S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
PT1814527E (pt) * 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007001067A2 (en) 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
TWI407978B (zh) 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
WO2007049292A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
US20080261958A1 (en) 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
RU2426530C2 (ru) * 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
US20080051438A1 (en) 2006-08-11 2008-02-28 Shinobu Nagahama Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
WO2008023958A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
BRPI0924136B8 (pt) 2009-01-23 2021-05-25 Hanmi Holdings Co Ltd composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma

Also Published As

Publication number Publication date
CN102292085A (zh) 2011-12-21
CN102292085B (zh) 2017-01-18
BRPI0924136B8 (pt) 2021-05-25
UA105203C2 (ru) 2014-04-25
EA201170959A1 (ru) 2011-12-30
TWI395583B (zh) 2013-05-11
JP2012515770A (ja) 2012-07-12
CR20110449A (es) 2011-11-10
PE20140978A1 (es) 2014-08-16
CN102292084A (zh) 2011-12-21
DOP2011000230A (es) 2011-10-15
IL214145A0 (en) 2011-08-31
MX2011006008A (es) 2011-06-28
HN2011002022A (es) 2014-02-03
ES2580777T8 (es) 2016-09-22
MX2011006061A (es) 2011-06-24
KR101232296B1 (ko) 2013-02-13
US20110245301A1 (en) 2011-10-06
UY32389A (es) 2010-02-26
EP2413931A1 (en) 2012-02-08
US9161933B2 (en) 2015-10-20
US8673945B2 (en) 2014-03-18
ZA201106162B (en) 2012-10-31
WO2010085014A1 (en) 2010-07-29
SA110310070B1 (ar) 2014-09-02
JO2981B1 (ar) 2016-09-05
EA201170958A1 (ru) 2012-01-30
EA019471B1 (ru) 2014-03-31
ECSP11011253A (es) 2011-09-30
AU2009338267B2 (en) 2014-09-18
EP2391365B1 (en) 2014-11-26
CA2749955C (en) 2016-07-26
TW201028151A (en) 2010-08-01
CN102292084B (zh) 2014-01-29
CA2749903A1 (en) 2010-07-29
MY151550A (en) 2014-06-13
ES2526606T3 (es) 2015-01-13
NZ594739A (en) 2013-11-29
US8673944B2 (en) 2014-03-18
TW201031404A (en) 2010-09-01
CA2749957C (en) 2016-07-26
CN105998017A (zh) 2016-10-12
JP5466716B2 (ja) 2014-04-09
NI201100144A (es) 2012-11-06
EP2391348A1 (en) 2011-12-07
UA102720C2 (ru) 2013-08-12
CR20110450A (es) 2011-11-10
SG173046A1 (en) 2011-08-29
UA102721C2 (uk) 2013-08-12
US20110245302A1 (en) 2011-10-06
EP2391365A2 (en) 2011-12-07
AU2009338251A1 (en) 2011-09-15
BRPI0924136A2 (pt) 2017-06-13
MX2011006009A (es) 2011-06-28
JO3328B1 (ar) 2019-03-13
IL214147A (en) 2016-08-31
SG173044A1 (en) 2011-08-29
ZA201106160B (en) 2012-10-31
AU2009338280A1 (en) 2011-09-15
CO6361915A2 (es) 2012-01-20
MY150974A (en) 2014-03-31
JP5660544B2 (ja) 2015-01-28
AU2009338251B2 (en) 2014-03-13
NZ594738A (en) 2013-11-29
MX349221B (es) 2017-07-19
MX345956B (es) 2017-02-28
IL214147A0 (en) 2011-08-31
BRPI0924137A2 (pt) 2019-09-24
ES2505116T3 (es) 2014-10-09
SG173045A1 (en) 2011-08-29
AR070897A1 (es) 2010-05-12
AU2009338267A2 (en) 2011-09-29
EA020103B1 (ru) 2014-08-29
CO6361905A2 (es) 2012-01-20
ES2580777T3 (es) 2016-08-26
WO2010085047A2 (en) 2010-07-29
NZ594740A (en) 2013-11-29
CO6361914A2 (es) 2012-01-20
PE20120428A1 (es) 2012-05-17
MA33058B1 (fr) 2012-02-01
EP2391348A4 (en) 2012-07-25
HK1163539A1 (en) 2012-09-14
WO2010085047A3 (en) 2010-11-04
TWI404534B (zh) 2013-08-11
CL2011001781A1 (es) 2012-03-23
HN2011002020A (es) 2014-02-03
KR20100086921A (ko) 2010-08-02
EP2391365A4 (en) 2012-07-25
JP2012515767A (ja) 2012-07-12
DOP2011000231A (es) 2011-10-15
KR101160151B1 (ko) 2012-06-27
AU2009338280B2 (en) 2014-05-01
DOP2011000229A (es) 2011-10-15
BRPI0924136A8 (pt) 2017-10-03
MX345868B (es) 2017-02-21
CN102292070A (zh) 2011-12-21
EA021763B1 (ru) 2015-08-31
MA33057B1 (fr) 2012-02-01
NI201100145A (es) 2012-08-17
BRPI0924136B1 (pt) 2019-10-15
MY173823A (en) 2020-02-24
KR20100086913A (ko) 2010-08-02
PE20100559A1 (es) 2010-09-12
US20110251245A1 (en) 2011-10-13
JP5658172B2 (ja) 2015-01-21
EP2413931B1 (en) 2016-06-01
AU2009338267A1 (en) 2011-09-15
BRPI0924135A2 (pt) 2016-02-10
AR075027A1 (es) 2011-03-02
CA2749957A1 (en) 2010-07-29
PE20100739A1 (es) 2010-11-19
IL214146A0 (en) 2011-08-31
ZA201106161B (en) 2012-10-31
CA2749903C (en) 2016-09-06
EP2413931A4 (en) 2012-08-08
WO2010085027A1 (en) 2010-07-29
CA2749955A1 (en) 2010-07-29
JP2012515768A (ja) 2012-07-12
EA201170960A1 (ru) 2012-01-30
EP2391348B1 (en) 2014-08-27
NI201100143A (es) 2012-08-17
CR20110448A (es) 2011-11-10
UY32388A (es) 2010-02-26
MA33056B1 (fr) 2012-02-01

Similar Documents

Publication Publication Date Title
AR075028A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
DOP2011000094A (es) Formulacion farmaceutica 514
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
BR112012024017A2 (pt) compostos derivados de triazina dissubstituída farmaceuticamemnte ativios, composição farmacêutica, método para a síntese destes e uso dos mesmos
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY32848A (es) Compuestos heterocíclicos de oxima
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
ECSP12011958A (es) Composiciones farmacéuticas que comprenden ligandos de receptores sigma
BR112015011430A2 (pt) composição para liberação imediata e prolongada
NI201000053A (es) Trans-clomifeno para el síndrome metabólico.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
CY1122084T1 (el) Συνθεσεις που περιλαμβανουν αμλοδιπινη και μπισοπρολολη
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов

Legal Events

Date Code Title Description
FC Refusal